Ixazomib
Ixazomib (pronunciation: ik-sa-zo-mib) is an antineoplastic agent used in the treatment of multiple myeloma. It is a proteasome inhibitor that works by blocking the action of proteasomes, thereby preventing the growth of cancer cells.
Etymology
The term "Ixazomib" is derived from the systematic IUPAC name for the compound, which is "N-[(1R)-1-[[(2,5-dichlorobenzoyl)amino]acetyl]-2,3-dihydro-1H-indol-6-yl]-3-(1-pyrrolidinyl)-1-[(1S)-1,2,3,4-tetrahydroisoquinolin-1-yl]-1,3-dihydro-2H-benzimidazol-2-one". The name "Ixazomib" was approved by the World Health Organization (WHO) in 2013.
Related Terms
See Also
References
- Ixazomib: a review in relapsed and/or refractory multiple myeloma. Drugs. 2017;77(16):1763-1773.
- Ixazomib, an investigational oral proteasome inhibitor, in patients with relapsed or refractory lymphoma: an overview of preclinical and phase 1 study results. Br J Haematol. 2014;167(4):461-469.
External links
- Medical encyclopedia article on Ixazomib
- Wikipedia's article - Ixazomib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski